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Although Bcl-XL and Bax are structurally similar, activated Bax forms large oligomers that permeabilize the outer
mitochondrial membrane, thereby committing cells to apoptosis, whereas Bcl-XL inhibits this process. Two different
models of Bcl-XL function have been proposed. In one, Bcl-XL binds to an activator, thereby preventing Bax activation.
In the other, Bcl-XL binds directly to activated Bax. It has been difficult to sort out which interaction is important in
cells, as all three proteins are present simultaneously. We examined the mechanism of Bax activation by tBid and its
inhibition by Bcl-XL using full-length recombinant proteins and measuring permeabilization of liposomes and
mitochondria in vitro. Our results demonstrate that Bcl-XL and Bax are functionally similar. Neither protein bound to
membranes alone. However, the addition of tBid recruited molar excesses of either protein to membranes, indicating
that tBid activates both pro- and antiapoptotic members of the Bcl-2 family. Bcl-XL competes with Bax for the
activation of soluble, monomeric Bax through interaction with membranes, tBid, or t-Bid-activated Bax, thereby
inhibiting Bax binding to membranes, oligomerization, and membrane permeabilization. Experiments in which
individual interactions were abolished by mutagenesis indicate that both Bcl-XL–tBid and Bcl-XL–Bax binding
contribute to the antiapoptotic function of Bcl-XL. By out-competing Bax for the interactions leading to membrane
permeabilization, Bcl-XL ties up both tBid and Bax in nonproductive interactions and inhibits Bax binding to
membranes. We propose that because Bcl-XL does not oligomerize it functions like a dominant-negative Bax in the
membrane permeabilization process.
Citation: Billen LP, Kokoski CL, Lovell JF, Leber B, Andrews DW (2008) Bcl-XL inhibits membrane permeabilization by competing with Bax. PLoS Biol 6(6): e147. doi:10.1371/
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Introduction
Apoptosis is a form of programmed cell death important
for development and tissue homeostasis, and its deregulation
has been implicated as the cause of many disease processes.
Apoptosis may be initiated by a developmental program and
by many diverse forms of cell stress. A critical feature of
metazoan apoptosis is the permeabilization of intracellular
organellar membranes that leads to the egress of intra-
organellar components that activate the proteases respon-
sible for cell death. Bcl-2 is the founding member of a family
that includes members that either prevent (e.g., Bcl-2 or Bcl-
XL) or promote (e.g., Bax or Bak) the membrane permeabi-
lization that leads to apoptosis. Another large subgroup of
the Bcl-2 family (BH3-only proteins; e.g., tBid) initiates
apoptosis through binding to Bax and/or Bcl-XL. Even though
Bcl-XL and Bax are structurally similar, experiments with
protein fragments and peptides or full-length protein in the
absence of membranes has led to the elaboration of models in
which the functional relevance of binding partners for Bcl-
XL differ. The direct activation [1,2] or hierarchical model [3]
states that Bcl-XL and other antiapoptotic Bcl-2 family
proteins inhibit apoptosis primarily through interactions
with a subclass of BH3-only proteins termed ‘‘activators’’,
preventing them from activating Bax and Bak. The indirect
activation model [4,5] proposes that the function of all BH3-
only proteins is to displace the inhibitory Bcl-XL from
inherently active Bax or Bak. Thus, these two models differ
primarily in whether Bax/Bak is constituively active or
requires activation and which interactions are crucial to the
antiapoptotic function of Bcl-XL. However, there is also
considerable overlap between these two competing models:
both models recognize that Bcl-XL directly binds to and
inhibits a proapoptotic Bcl-2 family protein that is directly
involved in membrane permeabilization, while other proa-
poptotic Bcl-2 family proteins indirectly induce apoptosis by
binding to Bcl-XL and preventing this function. Moreover,
some authors postulate that both models may be relevant in
different cell types or in the same cell type under different
circumstances (e.g., normal versus cancerous) [2,6]. Our
previous results have demonstrated the importance of
dynamic interaction of Bcl-2 family members with mem-
branes [7–9]. On the basis of these data and evidence from the
literature, we have proposed a model termed ‘‘embedded
together’’, in which interaction of these proteins with each
other changes after binding to the membrane as this causes
conformational changes that alter and/or expose new binding
surfaces [10,11]. Accordingly, a key feature for resolving
differences in the components and mechanisms of physio-
logically relevant interactions between Bcl-2 family members
is to examine these interactions in membranes.
To examine the molecular mechanism of membrane
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PLoS BIOLOGYpermeabilization for full-length Bcl-XL and Bax, we used
recombinant proteins and measured permeabilization of
both liposomes and mitochondrial outer membranes in vitro.
Recombinant tBid was used as an activator protein. Our
results demonstrate that Bcl-XL and Bax, despite having
opposite effects on apoptosis, share many functionally similar
features: in the absence of an activator, neither protein
bound tightly to membranes, whereas the addition of
membrane-bound tBid to Bax or Bcl-XL recruited a similar
molar excess of the soluble protein to membranes. However,
after binding to membranes, only Bax formed large oligomers
and permeabilized the membrane. Bcl-XL competes with Bax
for binding to both tBid and membrane-bound Bax as well as
for binding to membranes. In all cases, interaction of Bax
with Bcl-XL is nonproductive for membrane permeabiliza-
tion, presumably because Bcl-XL does not oligomerize. Thus,
we propose that Bcl-XL functions similarly to a dominant-
negative Bax in tBid-initiated membrane permeabilization.
Results
To inhibit membrane permeabilization, Bcl-XL might
inhibit any or all of the interactions of Bax and its activator
with each other or with membranes. There are many
potential activators of Bax, including but not limited to the
BH3-only proteins Bid, Bim, and Puma as well as other non-
Bcl-2 family proteins such as p53 [12,13] and Bif-1 [14,15].
While studies using cells or animals in which speciﬁc
components of the apoptotic pathway have been eliminated
have contributed substantially to our understanding, it would
be technically difﬁcult if not impossible to create mouse
stains with all of the relevant genes knocked out. Hence,
precisely which step(s) in the process are inhibited by Bcl-XL
as well as the molecular mechanism of inhibition can be best
determined by using a cell-free system in which each step can
be examined individually. To eliminate complications from
all other known and unknown proteins, metabolites, and
post-translational modiﬁcations that may contribute addi-
tional levels of regulation, we used a cell-free system
composed of highly puriﬁed full-length recombinant pro-
teins, without N- or C-terminal tags, and as a source of
membranes either liposomes with mitochondria-like compo-
sition [16] or subcellular fractions containing mitochondria.
As a representative activator protein, we used the caspase-8
cleavage product of Bid (tBid) to activate Bax. This protein
drives Bax/Bak-dependent permeabilization of mitochondria
[17,18] and also binds directly to antiapoptotic proteins such
as Bcl-XL and Bcl-2 [19].
The large increase in ﬂuorescence that accompanies the
release of the ﬂuorophore/quencher pair 8-aminonaphtha-
lene 1,3,6-trisulfonic acid (ANTS)/p-xylene-bis-pyridinium
(DPX) from liposomes was used to measure Bax-dependent
membrane permeabilization and its inhibition by Bcl-XL [7].
As seen previously, single addition of recombinant Bax (100
nM) or tBid (20 nM) to liposomes had little effect, but in
combination the two proteins caused an increase in
ﬂuorescence due to membrane permeabilization (Figure
1A). This result is consistent with previous observations that
tBid-activated Bax caused permeabilization of mitochondria
in cells [19], isolated mitochondria [8,9], and liposomes [16].
Bcl-XL Prevents Membrane Binding by Bax
The earliest step in the process leading to membrane
permeabilization that could be inhibited by Bcl-XL is binding
of tBid or Bax to the membrane. In incubations of 20 nM tBid
and liposomes, tBid bound effectively to liposomes as assayed
by gel ﬁltration chromatography (Figure 1B). Without tBid,
Bax (100 nM) did not bind to liposomes, as expected from
results seen in vitro and in cells [20]. However, when the two
proteins were added together, 20 nM tBid caused most of the
Bax to bind liposomes. The stoichiometry of this interaction
conﬁrms that one tBid molecule can directly or indirectly
recruit multiple Bax molecules to membranes [21]. The
resulting membrane permeabilization released ANTS/DPX
and larger encapsulated ﬂuorophores (Figure S1A) as well as
ﬂuorescent proteins of similar mass to the proteins released
from the intermembrane space of mitochondria during
apoptosis (unpublished data).
Addition of recombinant Bcl-XL inhibited tBid/Bax-medi-
ated liposome permeabilization in a concentration-depend-
ent manner (Figure 1A) with an IC50 of ;25 nM at the 2 h end
point. Furthermore, the shape of the inhibition curve (Figure
S1B) suggests that Bcl-XL inhibits ANTS/DPX release com-
petitively. At all effective concentrations of Bcl-XL, mem-
brane binding by Bax was efﬁciently inhibited (Figures 1B
and 3), as has been observed previously in cells [22] and for
mitochondria [18]. While Bax membrane binding was
inhibited, Bcl-XL had no effect on tBid binding to mem-
branes (Figure 1B). These results argue that Bcl-XL inhibits
membrane permeabilization by preventing the binding of
Bax, but not tBid, to membranes.
To conﬁrm that Bcl-XL inhibited tBid-induced binding of
Bax to biological membranes, mitochondria puriﬁed from
mouse liver (MLM) of bak –/– mice were assayed. MLM from
bak –/– mice also lack Bax as it is a cytoplasmic protein in
liver. Like liposomes, these mitochondria were resistant to
tBid, as outer mitochondrial membrane (OMM) permeabili-
zation, measured by the release of cytochrome c, required the
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Author Summary
During development and under stress, cells can become committed
to die via programmed cell death (apoptosis). In most cases, the
permeabilization of the outer mitochondrial membrane is a key
component of this commitment. The membrane permeablization
step is both positively and negatively regulated by members of the
Bcl-2 family of proteins. One member of this protein family with only
a BH3 region, such as tBid, activates another family member, Bax,
causing it to form large complexes that generate membrane-
spanning pores, hence making the membrane permeable. Anti-
apoptotic members of the Bcl-2 family, such as Bcl-XL, are
structurally similar to Bax but inhibit the membrane permeabiliza-
tion process by an unknown mechanism. Two mutually exclusive
models have been proposed to explain how the Bcl-2 family is
operating: one states that Bcl-XL binds to tBid, thereby preventing
Bax activation, while the second suggests that Bcl-XL binds directly
to activated Bax. It has been difficult to sort out which interaction is
important in cells, where multiple members of all three protein
families are present simultaneously. Here, we describe an in vitro
system containing the three recombinant proteins and the use of
mutagenesis to selectively remove individual interactions. We show
that Bcl-XL inhibits Bax by competing with it for binding to
membranes, tBid, and activated Bax. Because Bcl-XL does not form
pores, it inhibits apoptosis by acting as if it is a dominant-negative
version of Bax.addition of both tBid and Bax (Figure 1C). As seen with
liposomes, Bcl-XL inhibited tBid/Bax-mediated cytochrome c
release. To assess the binding of recombinant Bax to
mitochondria, the organelles were incubated with or without
tBid or tBid and Bcl-XL, pelleted by centrifugation, and
analyzed by immunoblotting (Figure 1D). The addition of
tBid increased the level of membrane-bound Bax and caused
the integration of Bax into the OMM, as assessed by resistance
to carbonate extraction, while the addition of Bcl-XL
inhibited these effects, conﬁrming our results obtained with
liposomes. As expected, tBid was sufﬁcient to induce
permeabilization of OMM isolated from wild-type mice (as
these mitochondria contained Bak), and Bcl-XL inhibited this
permeabilization (unpublished data).
Figure 1. Bax and tBid Cooperate To Induce Liposome Permeabilization, Which Is Inhibited by Bcl-XL
(A) Liposomes encapsulated with ANTS and DPX were incubated with 100 nM Bax, 20 nM tBid, or both (left panel) or with 100 nM Bax, 20 nM tBid, and
the indicated concentrations of Bcl-XL (right panel). Membrane permeabilization was assayed by an increase of ANTS fluorescence.
(B) Liposome binding of tBid, Bax, and Bcl-XL. The proteins, at the indicated concentrations, were incubated with liposomes. Membrane-bound proteins
were separated from soluble proteins by Sepharose CL-2B gel filtration chromatography. Individual fractions were analyzed by immunoblotting (IB)
using Bid, Bax, or Bcl-XL antibodies, as indicated.
(C) Mitochondria from bak knockout mice were incubated with tBid (20 nM), Bax (100 nM), and Bcl-XL (100 nM), as indicated. Permeabilization was
assayed by pelleting the mitochondria and analyzing both the pellet (P) and the supernatant (S) fractions by immunoblotting using an a-cytochrome c
antibody.
(D and E) Mitochondria were incubated with the indicated proteins (concentrations as in (C)) and the levels of (D) Bax or (E) Bcl-XL assayed in the
mitochondrial pellet. Integration of Bax or Bcl-XL into mitochondrial membranes was assayed by carbonate extraction, using Hsp60 (a soluble matrix
protein) as a control.
doi:10.1371/journal.pbio.0060147.g001
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the IC50 of ;25 nM Bcl-XL for inhibition of liposome
permeabilization is consistent with other published models
suggesting Bcl-XL sequestration of Bax/Bak activators (in this
case tBid) as one mechanism by which Bcl-XL could inhibit
membrane binding by Bax.
Membrane-Bound tBid Recruits Excess Bcl-XL to
Membranes, Where It Binds tBid and Bax
Alone, Bcl-XL showed minimal liposome binding, consis-
tent with cytoplasmic or loosely membrane-bound local-
izations reported for Bcl-XL in live cells [23,24] (Figure 1B).
However, 20 nM tBid caused migration of ;80 nM Bcl-XL to
liposomes both when the two proteins were added together
(Figure 1B, quantiﬁed in Figure 4B) and when tBid was bound
to liposomes before Bcl-XL was added (unpublished data).
The stoichiometry of this interaction indicates that, similar to
the effect on Bax, one tBid molecule recruits multiple Bcl-XL
molecules. When MLM from bak –/– mice were used as the
membrane source, the addition of tBid markedly increased
the levels of membrane-integrated Bcl-XL. As a result, the
Bcl-XL, which was almost entirely peripherally attached in
the absence of tBid, integrated in the OMM in the presence of
tBid (Figure 1E).
When both proteins were in the membranes, Bcl-XL bound
to tBid, as assessed by co-immunoprecipitation. This inter-
action was not dependent on the detergent used to solubilize
the liposomes (unpublished data), and at concentrations of
100 nM Bcl-XL and 20 nM tBid the interaction was not
affected by the addition of Bax (Figure 2A, left panel, lanes 1
and 2). In the absence of membranes, interaction between
Bcl-XL and tBid could not be detected by co-immunopreci-
pitation (unpublished data). Therefore, sequestering mem-
brane-bound tBid represents one mechanism whereby Bcl-XL
could inhibit apoptosis (Figure 6C, step 4). The recruitment
of multiple Bcl-XL molecules by a single molecule of
membrane-bound tBid increases the likelihood that tBid will
be sequestered by Bcl-XL, thereby increasing how effectively
Bcl-XL competes with Bax for tBid binding. Furthermore,
when Bcl-XL prevented tBid/Bax-mediated membrane per-
meabilization (Figure 1A), Bcl-XL was overwhelmingly mem-
brane-bound (Figure 1B). Thus, contrary to models that
propose that membrane integration would inactivate Bcl-XL
[25], our results suggest that tBid is required to cause a
conformational change in Bcl-XL that allows it to insert into
membranes where it may inhibit tBid (Figure 6B).
Although sequestration of membrane-bound tBid by Bcl-
XL appears to account for its antiapoptotic function in both
liposomes and MLM, we sought to determine whether Bcl-XL
also could interact stably with Bax. When tested in the
absence of tBid, a stable interaction between Bax and Bcl-XL
was not detected (Figure 2A, left panel, lane 3), suggesting
that Bcl-XL does not sequester Bax in solution. However as
expected, co-immunoprecipitation of Bcl-XL and Bax was
observed in control experiments where membranes were
solubilized with the nonionic detergent NP-40, known to
induce a conformational change in Bax required for
heterodimerization with Bcl-XL that is also seen in cells
when apoptosis is induced [20,26].
When tested in the presence of tBid (20 nM) and
membranes, we did not detect an interaction between Bcl-
XL (100 nM) and Bax (100 nM) (Figure 2A, left panel, lane 2).
Rather, Bcl-XL out-competed Bax for binding to both tBid
and membranes. In these incubations, Bcl-XL may not bind
Bax because they are not in the same compartment; Bcl-XL is
almost completely membrane-bound while Bax is soluble
(Figure 1B). Therefore, the same experiment was performed
using 20 nM Bcl-XL, a concentration at which Bcl-XL
competes less efﬁciently with Bax for binding to tBid,
allowing some Bax to become membrane-bound. Under these
conditions, Bcl-XL marginally inhibited membrane perme-
abilization (Figure 1A) and coprecipitated with Bax in
CHAPS buffer (Figure 2A, right panel, lane 2). The addition
Figure 2. Bcl-XL Binds to Membrane-Bound tBid and Bax
(A) Bax (100 nM) and/or tBid (20 nm) were incubated with 100 nM Bcl-XL
(left panel) or 20 nM Bcl-XL (right panels) and liposomes. Samples were
immunoprecipitated (IP) in either 2% CHAPS or 0.2% NP-40, as indicated,
using an antibody with the indicated specificity and immunoblotted (IB)
for the indicated protein.
(B–D) Mutations prevent the binding of Bcl-XL to tBid, Bax, or both. (B
and D) Bcl-XL (20 nM), or the indicated Bcl-XL mutants, (C) Bcl-XL Y101K
or (D) Bcl-XL DBH4, were incubated with (C and D) 20 nM tBid or (B) tBid-
mt1 with or without Bax (100 nM) and with liposomes. Immunopreci-
pitations and immunoblotting were performed as in (A).
doi:10.1371/journal.pbio.0060147.g002
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(compare lanes 1 and 2), suggesting that under conditions
where Bcl-XL cannot fully out-compete Bax for access to tBid
the presence of membrane-bound Bax provides a second
target for binding by Bcl-XL (Figure 6C, step 5).
Taken together, our results indicate that Bcl-XL and Bax
compete for binding to tBid and that Bcl-XL prevents
membrane permeabilization by forming stable heterodimers
with the membrane-bound forms of both tBid and Bax.
However, because both interactions are present when Bcl-XL
is active, it is possible that one particular interaction
contributes more to the antiapoptotic function of Bcl-XL
than the other, as has been proposed alternately by two
competing models of apoptosis [3,4].
Binding of Membrane-Bound Bcl-XL to tBid and Activated
Bax Each Contribute Significantly to Inhibition of
Membrane Permeabilization
To assess the relative contributions of Bcl-XL binding to
tBid and Bax to antiapoptotic function, these interactions
were selectively removed through mutagenesis. A tBid mutant
with substitution of two residues within the BH3 domain
(M97A/D98A of murine Bid, denoted tBid-mt1) does not bind
stably to Bcl-XL but binds to Bax [27]. Consistent with this
previous report, in our assay system tBid-mt1efﬁciently
recruited Bax to membranes where Bax was activated
(unpublished data), but tBid-mt1 did not coprecipitate with
Bcl-XL (Figure 2B). Thus, tBid-mt1 allows the selective
removal of the Bcl-XL–tBid interaction. Conversely, a
Figure 3. Bcl-XL Binds Both tBid and Bax To Prevent Membrane Permeabilization
(A) Liposomes encapsulated with ANTS and DPX were incubated with 100 nM Bax, 20 nM tBid or tBid-mt1, and increasing concentrations of Bcl-XL, Bcl-
XL Y101K, or Bcl-XL DBH4. Membrane permeabilization was assayed as in Figure 1A and is presented as percentage of ANTS/DPX release mean 6
standard deviation for at least three independent experiments.
(B) Mitochondria isolated from bak knockout mouse livers (bak –/– MLM) were incubated with 200 nM Bax, 250 pM tBid or tBid-mt1, and increasing
concentrations of Bcl-XL or Bcl-XL Y101K, as indicated. Permeabilization was assayed by pelleting the mitochondria and analyzing both the pellet (P)
and the supernatant (S) fractions by immunoblotting using an a-cytochrome c antibody.
(C) Results from experiments as in (B) quantified as percentage of cytochrome c release mean 6 standard deviation for at least three independent
experiments.
(D) Mitochondria isolated from wild-type mouse livers (wt MLM) were assayed as in (B) except that the concentration of tBid was reduced 10-fold to 25
pM. Permeabilization was quantified as in (C).
doi:10.1371/journal.pbio.0060147.g003
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prevents stable binding to Bax [28]. As expected, Bcl-XL
Y101K bound tBid but did not bind to activated Bax (Figure
2C), even in the presence of NP-40 detergent. Therefore,
using Bcl-XL Y101K allows the selective removal of Bcl-XL–
Bax binding. Combining these two mutants creates a situation
where Bcl-XL does not bind stably to either tBid or Bax
(unpublished data). As a negative control, we used Bcl-XL
with a deletion of the BH4 domain (amino acids 4–24) that
has been reported to remove binding to both Bax and the
BH3-only protein Bad [29]. In our assay, DBH4 Bcl-XL did not
coprecipitate tBid and bound very inefﬁciently to activated
Bax (Figure 2D). Addition of the Y101K point mutation to
DBH4 Bcl-XL to further remove Bax binding did not reduce
this residual interaction (unpublished data), indicating that it
is nonspeciﬁc. Therefore, these mutants behave similarly in
live cells and in our cell-free system.
By assay of ANTS/DPX release from liposomes for different
combinations of these proteins, the residual function of Bcl-
XL can be measured in the absence of stable interaction with
tBid, Bax, or both. The relative effects of each mutant were
tested by examining the concentration-dependent inhibition
of tBid/Bax-mediated liposome permeabilization by Bcl-XL
(Figure 3A). When tBid was replaced by tBid-mt1, Bcl-XL
continued to inhibit membrane permeabilization and bound
Bax activated by tBid-mt1 (Figure 2B). This indicates that a
signiﬁcant amount of Bcl-XL activity does not require Bcl-
XL–tBid binding, as has been suggested previously by some
[30] but not other models [3,31,32].
Removal of the Bcl-XL–Bax interaction by using Bcl-XL
Y101K decreased the activity of Bcl-XL somewhat (Figure 3A),
consistent with previously published results [33]. Never-
theless, the protein offered signiﬁcant protection from tBid/
Bax-induced dye release from liposomes. Thus, the loss of
tBid or Bax binding to Bcl-XL can be compensated by the
other binding interaction. The combination of tBid-mt1 and
Bcl-XL Y101K or DBH4 Bcl-XL (situations in which Bcl-XL
binds stably to neither tBid nor Bax) greatly reduced the
activity of Bcl-XL but did not eliminate it completely. To
address the possibility that this remaining activity was the
result of residual Bcl-XL–tBid or Bcl-XL–Bax interactions at
elevated concentrations of Bcl-XL, we examined the effects of
the tBid-mt1 and Bcl-XL Y101K mutations on Bcl-XL–tBid
and Bcl-XL–Bax interactions by co-immonoprecipitation at
Bcl-XL concentrations higher than those shown in Figure 2
(Figure S2). To detect the interactions of Bcl-XL with tBid-
mt1 as well as Bcl-XL Y101K with Bax required elevated
concentrations of Bcl-XL and/or prolonged immunoblot
exposures compared to the wild-type proteins, suggesting
that these residual interactions either are nonspeciﬁc or
contribute very little to the remaining antiapoptotic activity
seen with the tBid-mt1/Bcl-XL Y101K combination. To test
this possibility further, we combined the tBid-mt1/Bcl-XL
Y101K and DBH4 Bcl-XL mutations. This combination of
mutations (tBid-mt1 with DBH4 Bcl-XL Y101K) did not
further diminish Bcl-XL function (unpublished data), sug-
gesting that this remaining activity does not involve stable
protein–protein interactions. This residual function of Bcl-
XL is addressed below.
The effects of these proteins also were assessed for the
regulation of cytochrome c release from isolated mitochon-
dria (Figure 3B–D). By the use of bak –/– MLM (Figure 3B,
quantiﬁed in Figure 3C), Bcl-XL inhibited tBid/Bax-induced
membrane permeabilization in a dose-dependent manner, as
was seen in liposomes. Substitution of tBid-mt1 or Bcl-XL
Y101K for the respective wild-type proteins only slightly
reduced the prevention of cytochrome c release by Bcl-XL.
Using these two mutants together markedly reduced but did
not eliminate the inhibition of cytochrome c release by Bcl-
XL, similar to the residual activity noted with liposome
permeabilization. When wild-type MLM that contained BAK
were used, it was necessary to reduce the concentration of
tBid 10-fold to 25 pM to prevent it from activating sufﬁcient
Bak to cause OMM permeabilization. At this concentration of
tBid, cytochrome c release required the addition of Bax
(unpublished data), and the activity of Bcl-XL was similar to
that seen with bak –/– MLM (Figure 3D). In these incubations,
substitution of the wild-type proteins with tBid-mt1, Bcl-XL
Y101K, or both showed similar effects to those seen in bak –/–
MLM and liposomes (Figure 3C). Thus, in contrast to widely
promulgated models for the antiapoptotic mechanism of Bcl-
Figure 4. Bcl-XL Binding to Membranes and Bcl-XL-Mediated Inhibition
of Bax Membrane Binding Are Mediated by Interactions with tBid and
Bax
(A) Quantification of Bax binding to membranes. Bax (100 nM) and tBid
(20 nM) or tBid-mt1 were incubated with liposomes in the presence of
increasing concentrations of Bcl-XL, Bcl-XL Y101K, or Bcl-XL DBH4.
Membrane-bound protein was separated from soluble protein by
Sepharose CL-2B gel filtration chromatography and quantified by
immunoblotting. Results are presented as mean 6 standard deviation
for at least three independent experiments.
(B) Quantification of Bcl-XL and Bcl-XL mutant protein binding to
membranes. Bcl-XL, Bcl-XL Y101K, or Bcl-XL DBH4 (100 nM) was
incubated with the indicated proteins and analyzed as above. Results
are presented as mean 6 standard deviation for at least three
independent experiments. Black bars indicate experiments directly
comparable between (A) and (B).
doi:10.1371/journal.pbio.0060147.g004
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relevant membrane targets indicate that Bcl-XL binding to
Bax and tBid are both functionally relevant, but neither is
paramount.
Membrane-Bound Bcl-XL Inhibits Bax Binding to
Membranes Via Multiple Mechanisms
Although our results indicate that Bcl-XL inhibits tBid-
mediated activation of Bax by sequestering tBid in a stable
complex, it is unclear how Bcl-XL inhibits Bax binding to
membranes. For example, Bcl-XL might inhibit Bax binding
to membranes by preventing it from interacting with tBid.
Alternatively or in addition, Bcl-XL might directly inhibit Bax
binding to membranes. To determine the mechanism(s)
involved, we measured Bax liposome binding by gel ﬁltration
chromatography for reactions containing the different
mutant proteins (Figure 4A).
The absence of a stable interaction between tBid-mt1 and
Bcl-XL signiﬁcantly decreased Bcl-XL-mediated inhibition of
Bax binding to membranes at all tBid concentrations assayed.
Consequently, signiﬁcantly more Bax bound to membranes in
reactions containing tBid-mt1 compared to otherwise iden-
tical reactions containing tBid (p , 0.005 for 100 nM Bcl-XL,
p , 0.05 for 40 nM Bcl-XL, p , 0.1 for 20 nM Bcl-XL).
However, contrary to the prediction of some models [34], Bcl-
XL sequestering of tBid is only a contributing factor, as in the
absence of tBid binding Bcl-XL still dramatically reduced Bax
binding to membranes (Figure 4A, compare lanes 5–8).
It has been suggested that the multi-BH-region proapop-
totic proteins Bax and Bak autoactivate after tBid (or another
BH3-only protein) initiates the process and that autoactiva-
tion is inhibited by Bcl-2 [21,35]. In our system, one
consequence of Bax autoactivation would be recruitment of
soluble Bax to membranes. Therefore, in the absence of Bcl-
XL/tBid heterodimerization, Bcl-XL may inhibit recruitment
of Bax by binding to membrane-bound Bax and inhibiting
Bax autoactivation. To address this possibility, we substituted
Bcl-XL with the Bax-binding-deﬁcient Bcl-XL Y101K and
assayed Bax binding to liposomes in the presence of tBid-mt1
(Figure 4A, lanes 9–12). In reactions containing Bcl-XL
Y101K, signiﬁcantly more Bax bound membranes (p , 0.005
for 100 nM Bcl-XL, p , 0.05 for 40 nM Bcl-XL, p , 0.1 for 20
nM Bcl-XL), indicating that the interaction of Bcl-XL and Bax
inhibits further Bax binding to membranes. To determine
whether the Bcl-XL/Bax heterodimer also prevented the
subsequent oligomerization of Bax, we examined oligomeri-
zation by cross-linking. In these experiments, the cross-linker
was added to reactions containing an equal amount of
membrane-bound Bax in the absence or presence of Bcl-XL
(Figure S3). In these reactions, membrane-bound Bcl-XL
inhibited Bax oligomerization, as detected by cross-linking
concomitant with inhibition of dye release from liposomes.
Taken together, these results suggest that, when bound to Bcl-
XL, Bax function is neutralized, both in recruitment of other
Figure 5. Membrane-Bound Bcl-XL Inhibits the Liposome-Induced
Conformational Change in Bax
(A) Bax (100 nM) was incubated in the presence of liposomes and in the
absence or presence of tBid (20 nM). Conformation-altered Bax was
immunoprecipitated using the 6A7 antibody with or without the
addition of 2% CHAPS to solubilize the liposomes prior to immunopre-
cipitation and analyzed by immunoblotting using an a-Bax antibody. The
asterisk denotes the light chain of the 6A7 antibody.
(B) Bax was incubated in the presence of liposomes, tBid, and increasing
concentrations of Bcl-XL. Immunoprecipitations and immunoblotting
were performed as in (A) without the addition of 2% CHAPS.
(C) Bax was incubated for 2 h with liposomes (without tBid) at increasing
concentrations of Bcl-XL or Bcl-XL Y101K. Immunoprecipitations and
immunoblotting were performed as in (B).
(D and E) Bcl-XL inhibits liposome-induced cross-linking of Bax. (D) Bax
(100 nM) was incubated with liposomes for 2 h either alone (left panel),
with 20 nM tBid (middle panel), or with 20 nM tBid and 100 nM Bcl-XL
(right panel). Cross-linking with DSS was performed for 30 min at room
temperature with or without 2% CHAPS to solubilize the liposomes prior
to cross-linking, as indicated. Results were analyzed by immunoblotting.
(E) Bax (100 nM) was incubated with or without liposomes for 2 h. Cross-
linking and immunoblotting were performed as in (D).
(F) Membrane-bound Bcl-XL inhibits the liposome-induced Bax con-
formational change with 50 lM m1Bid but not with 50 lM Bak BH3
peptide. Immunoprecipitations and immunoblotting were performed as
in (B).
doi:10.1371/journal.pbio.0060147.g005
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to permeabilize membranes (Figure 6C, step 6).
Similar to results obtained by examining liposome per-
meabilization, there is a residual activity of the tBid-mt1/Bcl-
XL Y101K combination that prevented Bax binding to
membranes even in the absence of a stable interaction of
Bcl-XL Y101K with either tBid or Bax. This activity also was
observed for a DBH4 mutant of Bcl-XL (Figure 4A, lanes 13,
14).
At the onset of apoptosis in cells, Bcl-XL binds to
membranes [23]. The addition of tBid is sufﬁcient to trigger
Bcl-XL to bind to membranes in vitro (Figure 1B). Because
the membrane appears to be the active locus, we used the
mutant versions of Bcl-XL and tBid to examine the
importance of stable binding to tBid or Bax for Bcl-XL to
bind tightly to membranes (Figure 4B). In a negative control
experiment without other added proteins, less than 10 nM of
the added Bcl-XL (100 nM) bound to membranes (Figure 4B,
lane 1). Addition of Bax to the incubation did not increase
membrane binding by Bcl-XL (lane 2). As noted above (Figure
1B), a substoichiometric amount of tBid (lane 3) caused ;80
nM Bcl-XL to bind to membranes, suggesting that each tBid
molecule recruited three to four Bcl-XL molecules. Mem-
brane binding by Bcl-XL was reduced greatly when tBid was
substituted by tBid-mt1, indicating that stable Bcl-XL–tBid
binding can recruit Bcl-XL (lane 5). However, the addition of
Bax and tBid-mt1 (lane 6) caused the near complete recruit-
ment of Bcl-XL (;85 nM membrane-bound). Under these
conditions, the concentration of membrane-bound, activated
Bax is only ;15 nM (Figure 4A, lane 8), yet the concentration
of membrane-bound Bcl-XL increases by ;60 nM above that
seen with tBid-mt1, indicating that similar to tBid each
activated Bax molecule recruits about four Bcl-XL molecules.
Thus, like tBid, tBid-activated Bax recruits both soluble Bax
and Bcl-XL. Surprisingly, when both soluble Bax and Bcl-XL
are present, it appears that activated Bax recruits Bcl-XL
more efﬁciently than it recruits Bax. Therefore, another way
that Bcl-XL inhibits recruitment of Bax is by competing with
it for activated Bax on the membrane.
The Bax-binding-deﬁcient mutant Bcl-XL Y101K directly
and efﬁciently binds liposomes (Figure 4B, lanes 7–9). This is
presumably due to the location of this mutated residue in the
BH3 binding pocket suggested to house the C-terminal
membrane anchor of soluble Bcl-XL based on structural
similarity with Bax [36] or to bind the C-terminal membrane
anchor of an another Bcl-XL molecule as a cytoplasmic
homodimer [33]. In either case, spontaneous binding of Bcl-
XL Y101K to membranes may be due to displacement of the
C-terminal membrane anchor as a result of the Y101K
mutation.
The functional importance of membrane binding by Bcl-
XL is supported further by our observations that when Bcl-
XL inhibits membrane permeability in assays containing tBid
and Bax almost all of the Bcl-XL is membrane-bound and is
in stoichiometric excess over membrane-bound tBid and Bax
(Figure 4A and 4B, black bars), even when using mutants that
prevent heterodimerization with one or both of the binding
partners. Consistent with a role for membrane binding,
removing the C-terminal tail that mediates membrane bind-
ing impaired but did not abolish Bcl-XL function (Figure S4),
similar to the results obtained in cells using the same mutant
[37]. However, removal of the C-terminal tail in the context of
the tBid-mt1 and Bcl-XL Y101K mutations completely
abolishes the remaining activity of Bcl-XL. It is possible
therefore that the antiapoptotic function of Bcl-XL that is
independent of stable interactions with tBid and Bax requires
that Bcl-XL is membrane-bound. In that case, the excess Bcl-
XL bound to membranes in the presence of tBid or activated
Bax could contribute to this function of Bcl-XL (see below).
Taken together, our results suggest that Bcl-XL prevents
recruitment of Bax to membranes by multiple mechanisms
(Figure 6C). These include: competition with Bax for binding
to and thereby sequestering tBid, inhibition of Bax autoacti-
vation by competing with soluble Bax for binding membrane-
Figure 6. Bcl-XL Functions Like a Dominant-Negative Bax
(A) Cytoplasmic Bax undergoes a conformational change after interact-
ing with membranes (step 1). Interaction of this peripheral membrane
(indicated by the shadow) Bax with membrane-bound tBid causes a
further conformational change such that Bax integrates in the membrane
in an oligomerization competent form (step 2). Conversely, cytoplasmic
Bax may interact with other activator proteins to integrate into
membranes, or spontaneously active Bax molecules may integrate into
the membrane without binding an activator protein. A single tBid
molecule activates multiple peripheral membrane Bax molecules, and/or
the activated integral membrane Bax recruits more cytoplasmic Bax to
the membrane (autoactivation, step 3). Bax oligomerizes.
(B) Bcl-XL exists in a cytoplasmic and/or a peripheral membrane-bound
form (step 1). Membrane-bound tBid triggers membrane binding and
activation of Bcl-XL (step 2). One tBid molecule can mediate the
membrane binding and activation of multiple Bcl-XL molecules (step 3).
Bcl-XL does not oligomerize.
(C) Membrane-bound Bcl-XL sequesters tBid and thereby prevents the
activation of Bax (step 4). Bcl-XL binds to membrane-bound Bax,
preventing Bax oligomerization (step 5) and the recruitment of further
peripheral Bax by autoactivation (step 6). In steps 4–6, Bcl-XL functions as
a dominant-negative Bax.
(D) Bcl-XL inhibits the conformational change of Bax (step 7, indicated as
a change in equilibrium) that is elicited by peripheral membrane binding
(step 1 in (A)).
doi:10.1371/journal.pbio.0060147.g006
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membrane-bound Bcl-XL.
Membrane-Bound Bcl-XL Prevents a Membrane-Induced
Reversible Bax Conformational Change
We hypothesized that the residual antiapoptotic function
of membrane-bound Bcl-XL that does not require stable
heterodimerization with tBid or Bax involves inhibiting the
transient Bax conformational change that occurs when Bax
interacts with the membrane surface and exposes an epitope
bound by the 6A7 monoclonal antibody [7]. Binding of 6A7
has been used widely as a marker for one of the stages
required for activation of Bax (reviewed in [10]). In vivo, this
conformational change has been observed for membrane-
bound Bax actively involved in membrane permeabilization
[38,39]. However, in experiments using liposomes, it is
evident that the exposure of this epitope occurs prior to
and is independent of Bax membrane insertion. The change
is presumed to result from an interaction of Bax with the
surface of the membrane because it rapidly reverses when
Bax is separated from the liposomes [7]. This liposome-
induced conformational change does not require tBid;
however, the epitope remains exposed after tBid-induced
Bax membrane insertion (Figure 5A, lanes 1 and 2). Unlike
the conformational change that accompanies tBid-induced
insertion of Bax into membranes, the liposome-induced
conformational change also disappears if liposomes are
solubilized in CHAPS prior to immunoprecipitation (Figure
5A, compare lanes 1 and 3).
As shown above, addition of Bcl-XL prevents tBid-induced
insertion of Bax into membranes and instead results in Bcl-
XL inserting into the membrane (Figures 1 and 4). However,
under these conditions the soluble Bax does not undergo the
liposome-induced conformation change (Figure 5B), suggest-
ing that the presence of membrane-bound Bcl-XL either
inhibits this conformational change or shifts the equilibrium
of Bax molecules interconverting between the two forms
sufﬁciently towards the 6A7-negative conformer that the
antibody no longer has sufﬁcient access to the epitope. As
previously described, soluble Bcl-XL had little effect on the
liposome-induced conformational change of Bax (Figure 5C,
top panel) [7]. In contrast, the spontaneous membrane
binding Bcl-XL Y101K mutant inhibits this conformational
change in Bax (Figure 5C, bottom panel).
To investigate further the effects of the membrane surface
on Bax and the inhibition of these effects by Bcl-XL, cross-
linking experiments using disuccinimidyl suberate (DSS) were
performed. Cross-linking of Bax into higher-order structures
after Bax binds to membranes has been observed previously
[18]. The incubation of Bax with liposomes alone does not
cause sufﬁciently tight membrane binding by Bax to survive
gel ﬁltration chromatography (Figure 1B). Nevertheless,
incubation with liposomes did result in the cross-linking of
Bax into higher-order complexes (Figure 5D, left panel). As
expected from previous results [7,9], the interactions between
Bax monomers induced by incubation with membranes were
not resistant to detergent solubilization prior to cross-
linking. The Bax–Bax cross-links were reduced in the absence
of liposomes (Figure 5E), suggesting that, similar to binding
by the 6A7 antibody, they result from a liposome-induced
conformational change in Bax. Addition of tBid to Bax and
liposomes resulted in a similar cross-linking pattern, but
these Bax oligomers were resistant to solubilization of the
membrane with detergent (Figure 5D, middle panel). Mem-
brane-bound Bcl-XL not only prevented the formation of
detergent-resistant Bax cross-links but also prevented the
cross-linking of Bax that resulted when Bax contacted the
membrane surface (Figure 5D, right panel). These results
further demonstrate that Bcl-XL in the membrane prevents
or reverses the conformational change in soluble Bax that
occurs upon exposure to a membrane surface.
To determine whether the effect of membrane-bound Bcl-
XL on this transient, liposome-induced conformational
change in Bax could be regulated, BH3 peptides were used
to induce selectively Bcl-XL binding to membranes (Text S1).
On the basis of the effects previously published for mutations
in BH3 domains of proapoptotic proteins and peptides, we
selected two peptides that both caused membrane binding by
Bcl-XL (Figure S5A) but differed in their functional effects
(Figure S5B). One peptide, designated m1Bid BH3, contain-
ing a single mutation for a conserved and critical leucine
residue, did not interfere with the antiapoptotic function of
Bcl-XL. The other peptide, Bak BH3, effectively eliminated
the antiapoptotic activity of Bcl-XL as assayed by liposome
permeabilization assays. The effects of these peptides indicate
that membrane-bound Bcl-XL can exist in both functional
and nonfunctional states.
To determine whether the functional state of membrane-
bound Bcl-XL affected the inhibition of the liposome-
induced conformational change in Bax, the m1Bid BH3 and
Bak BH3 peptides were used to trigger membrane binding by
Bcl-XL in the presence of soluble Bax. In the absence of Bcl-
XL, neither peptide induced Bax membrane binding or Bax-
dependent membrane permeabilization (unpublished data).
When the m1Bid BH3 peptide triggered Bcl-XL binding to
membranes, the Bcl-XL still inhibited the liposome-induced
Bax conformational change (Figure 5F, top panel, lanes 2 and
3). In contrast, when the Bak BH3 peptide was added,
membrane-bound Bcl-XL did not prevent the liposome-
induced Bax conformational change (Figure 5F, bottom
panel, lanes 2 and 3). Therefore, inhibition of the liposome-
induced conformational change in soluble Bax by membrane-
bound Bcl-XL correlates with the functional status of Bcl-XL
on the membrane. Taken together, these results indicate that
this activity is a regulatable function of membrane-bound
Bcl-XL and is not merely the result of changes in the
biophysical properties of liposomes after Bcl-XL binding
(Figure 6D).
Discussion
To date, it has been a paradox that Bcl-XL and Bax have
very similar structures, yet proposed models for their
function all suggest that they behave very differently. Taken
together, our results suggest that they actually function
similarly to the extent that they compete with each other at
most steps of the process but with the major difference being
that Bcl-XL is defective for membrane permeabilization.
Thus, for most functions Bcl-XL behaves in a manner
conceptually similar to a dominant-negative Bax. Bcl-XL
inhibited membrane binding by Bax by competing with
soluble Bax for recruitment to membranes by either tBid or
membrane-bound Bax (Figure 6). Thus, similar to Bax, Bcl-XL
binds to both activated, membrane-bound Bax and mem-
PLoS Biology | www.plosbiology.org June 2008 | Volume 6 | Issue 6 | e147 1276
Bcl-XL Functions as a Dominant-Negative Baxbrane-bound tBid. Furthermore, Bcl-XL binding to Bax
inhibits the subsequent oligomerization of membrane-bound
Bax. Our results with mutations that disable either of these
interactions individually indicate that in membranes both are
functionally important.
Pioneering experiments to identify relevant binding
partners for Bcl-2 and Bcl-XL using immunoprecipitation
in transfected cells suggested a lack of correlation between
Bax binding and inhibition of apoptosis, as only certain Bcl-
XL point mutants that could no longer bind to Bax lost
function [40]. Further analysis of two of these Bcl-XL mutants
that did not bind to Bax (the F131V/D133A mutant that
remained functional and the inactive G138E/R139L/I140N
mutant) suggested that prevention of apoptosis required
binding to the BH3-only proteins tBid, Bim, and Bad, a
function that was speciﬁcally lost in the latter mutant [19].
However, as these experiments were conducted on whole cells
where Bax was also present, it is possible that the lack of
function of this mutant is caused by the loss of binding to
both BH3-only proteins (e.g., tBid) and Bax , a result entirely
consistent with our observations. Conversely, early work with
the M97A/D98A Bid mutant that does not bind to Bcl-XL
[27,30] that we have used in our study (tBid mt1) indicated
that Bcl-XL inhibited the apoptosis caused by this Bid
mutant, in cells and in puriﬁed mitochondria, implying that
the interaction with activated Bax rather than Bid was critical
to the antiapoptotic function of Bcl-XL in this context. Our
model reconciles these disparate results by postulating that
only after loss of both interactions does the antiapoptotic
function of Bcl-XL become severely diminished. While Bcl-
XL may inhibit OMM permeabilization initiated by the BH3-
only proteins Bid, Bim, and Puma by sequestering these
proteins, a variety of evidence now exists for alternate Bax
activation pathways (reviewed in [10]) that do not rely on
these BH3-only proteins. For many of these known and
potentially unknown pathways, Bcl-XL may not directly
sequester the initial activators of Bax, and hence inhibition
of membrane permeabilization may rely on the sequestration
of activated Bax to inhibit Bax autoactivation, oligomeriza-
tion, and membrane permeabilization.
Our results clearly show that the major functional
interactions of Bcl-XL occur after the protein has migrated
to the membrane, a process initiated in our in vitro system by
binding to either membrane-localized tBid or membrane-
localized (activated) Bax. Membrane insertion of both tBid
[41] and Bax [42] exposes the proapoptotic BH3 region of
each protein, an event that is critical for interaction with Bcl-
XL and likely initiates a conformational change in the
antiapoptotic protein that is required for membrane in-
sertion. Bcl-XL is found in both the cytoplasm as well as
attached to (but not inserted into) the mitochondrial
membrane in healthy cells. Migration of the cytoplasmic
fraction to membranes with insertion occurs during apopto-
sis [23,43,44] for Bcl-XL as well as other antiapoptotic
proteins such as Mcl-1 [44] and Bcl-w [25,45]. For Bcl-w,
interaction with a tethered Bim BH3 peptide displaces the C-
terminal insertion sequence from the BH3 binding pocket
within the protein triggering insertion of the protein into the
membrane [25,46]. Although a structure has not been
reported for Bcl-XL containing the C-terminal insertion
sequence, the structure of the truncated protein is sufﬁciently
similar to that of Bcl-w [46] and proapoptotic Bax [36] to
suggest displacement of the insertion sequence of Bcl-XL as a
mechanism that drives Bcl-XL into the membrane. In vitro
binding assays using protein lacking the C-terminal insertion
sequence have shown that Bcl-XL binds a variety of BH3
peptides [2,34]. For several of the peptides, structural studies
have conﬁrmed that the peptides bind in the hydrophobic
pocket that is also believed to bind the Bcl-XL insertion
sequence [47–49]. Furthermore, it has been reported pre-
viously that overexpression of Bad caused the membrane
insertion of Bcl-XL in HeLa cells [33]. We therefore
determined whether peptides from the BH3 regions of Bid,
Bim, Bad, Bax, and Bak caused insertion of Bcl-XL into
liposomes, assayed by ﬂotation on a sucrose gradient (Figure
S6). All ﬁve peptides caused Bcl-XL to insert into membranes,
while a mutant Bid peptide that fails to bind Bcl-XL [2] did
not.
In cells, it is likely that other BH3-only proteins will
substitute in many cases for tBid, and unlike Bid some of
these proteins may not be required themselves to bind to
membranes to expose the BH3 sequence. Nevertheless,
whether initiated in the cytoplasm or at the surface of the
membrane, interaction of Bcl-XL with a proapoptotic BH3
sequence is likely to be at least one of the factors that
contributes to the insertion of Bcl-XL into membranes.
Previous reports using transfected cells have indicated that
the removal of the C-terminal insertion sequence of Bcl-XL
severely impairs membrane insertion but has varying effects
on Bcl-XL function, from moderate [29] to severe [50]
reduction in function. Consistent with this variability, we
have shown previously [37] that the function of DTM Bcl-XL
compared to that of wild type is heavily dependent on the
stimulus used to initiate apoptosis (and therefore possibly the
BH3 protein(s) involved). In our in vitro system, DTM Bcl-XL
showed a severe loss of function (Figure S3) as the relevant
interactions here occur on membranes. However, in certain
circumstances in cells DTM Bcl-XL may retain at least part of
its antiapoptotic function in the cytoplasm depending on the
location of relevant binding partners at the onset of
apoptosis.
While we have focused our experiments on examining tBid
and its interactions with Bax and Bcl-XL, our studies do not
imply that tBid is an essential component of the membrane
permeabilization process. Instead, we predict that various
aspects of the functions of Bcl-XL and Bax revealed here can
be triggered differentially by the different BH3 proteins that
have been identiﬁed. Moreover, different BH3-only proteins
would be expected to exhibit differences in the relative
afﬁnities for and activities on Bax and Bcl-XL, as we have
described in our ‘‘embedded together’’ model [10]. However,
the previously reported binding afﬁnities between BH3
peptides and other Bcl-2 family members are unlikely to
accurately reﬂect binding afﬁnities at the physiologically
relevant locus of membranes. Clearly, it will be important to
determine more appropriate quantitative estimates for the
interactions of Bcl-2 family proteins in membranes.
Inhibition of the transient conformation change in Bax
that occurs at the membrane surface (Figure 6D) is the only
step in which inhibition of Bax activation is not due to Bcl-XL
functioning similar to a defective version of Bax. It is likely
that the conformational change in Bax at the membrane
surface enhances its activation by membrane-bound tBid.
Consistent with this interpretation, tethering of the soluble
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several orders of magnitude [51]. It is not known how
membrane-bound Bcl-XL prevents a transient change in the
conformation of Bax. However, it is not unreasonable to
speculate that it might do so by interacting transiently with
Bax to shift the equilibrium in Bax conformers sufﬁciently
toward the 6A7-negative conformation that the antibody
does not have sufﬁcient access to the epitope to bind it.
Our in vitro system recapitulates the core features of
organelle permeabilization by activated Bax and its inhibition
by Bcl-XL and has allowed us to identify and examine many
of the individual steps. The liposomes that we used to model
physiologic membranes have a high intrinsic curvature and
lipid composition that facilitate membrane binding of the
recombinant proteins and induction of the 6A7 conforma-
tional change in Bax. In cells, these feature are likely
represented by complex and dynamic physiologic processes
such as mitochondrial membrane ﬁssion and fusion shown to
be important in apoptosis [52–54] and the interaction of
mitochondria with other membrane systems [39,52,55]. The
major observations reported here were conﬁrmed for
cytochrome c release from mitochondria (Figure 3B–D),
suggesting that they will be relevant in live cells. Moreover,
the simplicity and power of our in vitro system using
recombinant proteins and membranes has allowed us to
identify and measure functionally important and potentially
‘‘druggable’’ interactions important for the regulation of
apoptosis (Figure 6).
Materials and Methods
Materials. The bak –/– mice were purchased from Jackson
Laboratories. ANTS and DPX were purchased from Molecular
Probes. BH3 peptides blocked at both ends (Ac-peptide-amide) were
obtained from Dalton Chemicals. The monoclonal Bax antibodies
2D2 and 6A7 were generous gifts from Richard Youle [26]. The
monoclonal tBid antibody 5C8 was obtained from Exalpha Bio-
logicals. The rabbit polyclonal antibody to Bcl-XL and the sheep
polyclonal antibody to cytochrome c were produced in our
laboratory. Immunoblotting of Bax was carried out using 2D2 at a
dilution of 1:10,000. Immunoblotting of Bcl-XL, tBid, and cyto-
chrome c was performed at dilutions of 1:10,000, 1:2,000, and 1:5,000,
respectively, with the appropriate antibody. Secondary antibodies
conjugated to horseradish peroxidase were purchased from Jackson
Immuno Research Laboratories and were used at dilutions of
1:10,000. Immunoblots were analyzed using ImageQuant (version
5.2, Molecular Dynamics). Statistical analysis was performed using a
one-way ANOVA model. All lipids were obtained from Avanti Polar
Lipids. DSS was purchased from Pierce.
Protein puriﬁcation. Recombinant full-length human Bcl-XL (or
Bcl-XL Y101K) with no additional amino acids was expressed in
Escherichia coli as a C-terminal intein/chitin-binding domain fusion
and puriﬁed by afﬁnity chromatography on a chitin column followed
by further puriﬁcation on a phenyl-Sepharose column, similar to a
method described previously [7] but with a ﬁnal dialysis step to
remove detergents. For DTM Bcl-XL (and the DTM Y101K mutant),
the phenyl-Sepharose chromatography step was omitted. Recombi-
nant full-length human Bax and murine tBid (or tBid-mt1) with no
additional amino acids were puriﬁed as described previously [7,9].
Membrane preparation and measurement of permeabilization.
Liposomes were composed of the following molar percentages of
lipids: phosphatidylcholine, 48%; phosphatidylethanolamine, 28%;
phosphatidylinositol, 10%; dioleoyl phosphatidylserine, 10%; and
tetraoleoyl cardiolipin, 4%. Liposome preparation, including ANTS/
DPX charged liposomes, was essentially as in [7], with the exception
that liposomes were prepared in assay buffer (10 mM HEPES (pH 7),
200 mM KCl, 5 mM MgCl2, and 0.2 mM EDTA). Samples (50 lM total
lipids) were prepared in assay buffer with all sample components
(buffers, liposomes, etc.) added prior to the addition of recombinant
proteins. Fluorescence (kex ¼ 355 nm and kem ¼ 520 nM) was
measured for 30 min at 37 8C in the presence of Bcl-XL but in the
absence of Bax and tBid to obtain background values (F0). Bax and
tBid (in that order) were added at t ¼ 0, and ﬂuorescence was
measured for 2 h at 37 8C. Triton X-100 was added to a ﬁnal
concentration of 0.2% (w/v), and ﬂuorescence was measured for 10
min at 37 8C( F100). The percentage release of ANTS/DPX was
calculated as percentage release ¼ ((F – F0)/(F100 – F0)) 3 100.
Membrane fractions containing mitochondria from C57bl6 mouse
liver were puriﬁed as described previously [56]. Samples were diluted
to 1 mg/ml total protein (Bradford assay), incubated with puriﬁed
proteins, added in the order Bcl-XL, Bax, and tBid, for 1 h at 30 8C,
then centrifuged at 13,000 g for 10 min. The supernatant and pellet
were separated and analyzed.
Membrane binding assays. Samples containing liposomes (300 lM
total lipids) were prepared in assay buffer and incubated at 37 8C for
2 h. All sample components (buffers, liposomes, etc.) were added
prior to the addition of recombinant proteins, which were added in
the order Bcl-XL, Bax, and tBid. Membrane-bound protein was
separated from soluble (‘‘free’’) protein using gel ﬁltration chroma-
tography on Sepharose CL-2B resin. Membrane binding was
measured by comparing the intensities of membrane-bound proteins
(fractions 3 and 4) with total proteins (fractions 3 and 4 plus fractions
8–11). Separation of membrane-bound protein from soluble (‘‘free’’)
protein by liposome ﬂoatation on a sucrose density gradient was
performed as previously described [57]. To assess the membrane
binding and membrane insertion of Bax and Bcl-XL into mitochon-
dria, puriﬁed proteins, added in the order Bcl-XL, Bax, and tBid,
were incubated for 1 h at 30 8C with mitochondria (5 mg/ml) from bak
–/– mice. Mitochondria were centrifuged at 7,000 g for 10 min. Pellets
were resuspended (50 ll) and treated with 800 ll of carbonate buffer
(200 mM sodium carbonate (pH 11.5), 10 mM DTT, and 2% glycerol)
for 30 min on ice. Samples (750 ll) were then overlayed onto a 0.5 M
sucrose cushion in carbonate buffer (250 ll) and centrifuged at
;200,000g for 30 min. The supernatant and sucrose cushion were
separated, neutralized with glacial acetic acid (5 ll per 250 ll sample),
and stored at  80 8C, or the proteins were precipitated with
trichloroacetic acid (18.75%). All immunoblots are representative
of at least three independent experiments.
Immunoprecipitation. Samples containing liposomes (300 lM total
lipids) were prepared and incubated as described in the ‘‘Membrane
binding assays’’ section. Immunoprecipitation of Bcl-XL was per-
formed using the polyclonal Bcl-XL antibody in assay buffer
containing either 2% CHAPS or 0.2% NP-40. Immunoprecipitates
were collected as previously described [7] and washed three times in
assay buffer containing the appropriate detergent. Immunoprecipi-
tation using the conformation-speciﬁc 6A7 Bax antibody was
performed on whole membranes and washed three times with assay
buffer containing 2% CHAPS. All immunoblots are representative of
at least three independent experiments.
DSS cross-linking. Samples containing liposomes (300 lM total
lipids) were prepared and incubated as described in the ‘‘Membrane
binding assays’’ section. DSS cross-linking was performed at a
concentration of 2 mM (or DMSO control) for 30 min at room
temperature. The cross-linker was quenched by the addition of Tris-
Cl (pH 8) to a ﬁnal concentration of 20 mM. To examine the effects of
CHAPS solubilization prior to cross-linking, samples were mixed with
an equal volume of assay buffer or assay buffer containing 4%
CHAPS, and the extent of cross-linking was analyzed. All immuno-
blots are representative of at least three independent experiments.
Supporting Information
Figure S1. Bax and tBid Cooperate To Induce Liposome Permeabi-
lization Allowing Egress of 10 kDa Dextran, Which Is Inhibited by Bcl-
XL
(A) Liposomes (300 lM total lipids) containing a rhodamine-PE tracer
(0.1% of total lipids) encapsulating Bodipy-labeled 10 kDa dextrans
(30 lM) were incubated with 100 nM Bax, 20 nM tBid, and the
indicated amounts of Bcl-XL. Liposomes were separated from
released dextrans by Sepharose CL-2B gel ﬁltration chromatography.
Bodipy (kex ¼ 460 nm and kem ¼ 518 nm, left panel) and rhodamine
(kex¼590 nm and kem¼610 nm, right panel). Excluded fractions (3–6)
contain liposomes and encapsulated dextrans. Included fractions (8–
13) contain dextrans released from liposomes. Fluorescence was
expressed as a percentage of the total.
(B) Bcl-XL inhibits liposome permeabilization competitively. Lip-
osomes (50 lM total lipids) encapsulating ANTS and DPX were
incubated with 100 nM Bax, 20 nM tBid, and the indicated
concentration of Bcl-XL. Membrane permeabilization was assayed
by an increase of ANTS ﬂuorescence and presented as mean 6
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IC50 value (25.5 nM) is indicated by the dashed line and was calculated
using Graphit software (version 1.10, Gecces Software Development).
Found at doi:10.1371/journal.pbio.0060147.sg001 (392 KB TIF).
Figure S2. Residual Binding of Bcl-XL to tBid-mt1 and Bcl-XL Y101K
to Bax
(A) Bax (100 nM) and 20 nM tBid (left) or tBid-mt1 (right) were
incubated with 20 or 100 nM Bcl-XL and liposomes. Samples were
immunoprecipitated (IP) in 2% CHAPS, using an antibody with the
indicated speciﬁcity, and immunoblotted (IB) for the indicated
protein. Normal (‘‘light’’) exposures are shown at the top while
excessive (‘‘dark’’) exposures are shown at the bottom. Input panels
represent 3% of the entire reaction while immunoprecipitation
panels represent 20% of the entire reaction.
(B) Bax (100 nM) and tBid-mt1 (20 nM) were incubated with 20 or 100
nM Bcl-XL (left) or Bcl-XL Y101K (right) and liposomes. Immuno-
precipitations and immunoblotting were performed as in (A), with
input panels representing 1% of the entire reaction and immuno-
precipitation panels representing 20% of the entire reaction.
Found at doi:10.1371/journal.pbio.0060147.sg002 (615 KB TIF).
Figure S3. Bcl-XL Binds to Bax in Membranes, Inhibiting Bax
Oligomerization and Membrane Permeabilization
(A) Bax, tBid-mt1, and Bcl-XL (as indicated) were incubated with
liposomes (300 lM total lipids). The membrane fraction was isolated
by Sepharose CL-2B gel ﬁltration chromatography and immuno-
blotted for Bax (top panel) or Bcl-XL (second panel). Cross-linking
with DSS (2 mM) was performed for 30 min at room temperature on
whole membranes and analyzed by immunoblotting for Bax (third
panel). When Bcl-XL is present, there is a large increase in the
amount of monomer and a decrease in the amount of cross-linked
species most noticeable for trimers and above. Bax and Bcl-XL
coprecipitated (fourth and ﬁfth panels) when membrane fractions
were immunoprecipitated with either antibody (indicated to the right
of the panels) and immunoblotted with the opposite antibody
(indicated to the left of the panels). The asterisk indicates the
antibody light chain.
(B) Liposomes (50 lM total lipids) encapsulating ANTS and DPX were
incubated with Bax, tBid-mt1, and Bcl-XL (as indicated). Membrane
permeabilization was assayed by an increase of ANTS ﬂuorescence.
Found at doi:10.1371/journal.pbio.0060147.sg003 (425 KB TIF).
Figure S4. Loss of Membrane Binding Inhibits the Residual Function
of a Heterodimerization-Incompetent Bcl-XL
(A) Bcl-XL or Bcl-XL Y101K lacking 23 C-terminal residues (DTM Bcl-
XL or DTM Bcl-XL Y101K) (100 nM) were incubated with liposomes
(300 lM total lipids), 100 nM Bax, and 20 nM tBid or tBid-mt1.
Membrane-bound protein was separated from free protein by
Sepharose CL-2B gel ﬁltration chromatography. Individual fractions
were analyzed by immunoblotting for Bcl-XL.
(B) Liposomes (50 lM total lipids) encapsulating ANTS and DPX were
incubated with 100 nM Bax, 20 nM tBid or tBid-mt1, and increasing
concentrations of DTM Bcl-XL, DTM Bcl-XL Y101K, or Bcl-XL
Y101K. Membrane permeabilization was assayed by an increase of
ANTS ﬂuorescence and is presented as mean 6 standard deviation
for at least three independent experiments.
Found at doi:10.1371/journal.pbio.0060147.sg004 (199 KB TIF).
Figure S5. Membrane-Bound Bcl-XL Can Be in a Functional or
Nonfunctional State
(A) Membrane binding of Bcl-XL can be triggered by BH3 peptides.
Left, sequences of peptides corresponding to the BH3 regions of Bid,
a Bcl-XL-binding mutant m1Bid, an inactive mutant m2BidBH3, and
Bak. Right, 100 nM Bcl-XL incubated with liposomes (300 lM total
lipids) and the indicated BH3 peptide (50 lM each). Membrane-
bound protein was separated from soluble protein by Sepharose CL-
2B gel ﬁltration chromatography, and individual fractions were
analyzed by immunoblotting for Bcl-XL.
(B) Membrane-bound Bcl-XL is functional (left panel) or nonfunc-
tional (right panel) when incubated with m1Bid BH3 or Bak BH3
peptide, respectively. Liposomes (50 lM total lipids) encapsulating
ANTS and DPX were incubated with the indicated concentration of
Bcl-XL and m1Bid BH3 peptide (left panel) or Bak BH3 peptide (right
panel) for 2 h prior to the addition of 100 nM Bax and 20 nM tBid.
Membrane permeabilization was assayed by an increase of ANTS
ﬂuorescence, and results are representative of at least three
independent experiments.
Found at doi:10.1371/journal.pbio.0060147.sg005 (1.0 MB TIF).
Figure S6. BH3 Peptides Induce Binding of Bcl-XL to Membranes
(A) Sequences of peptides corresponding to the BH3 regions of Bid,
an inactive mutant m2Bid, Bim, Bad, Bax, and Bak.
(B) Bcl-XL (100 nM) was incubated with liposomes (300 lM total
lipids) and the indicated BH3 peptide (50 lM each). Membrane-
bound protein was separated from soluble protein by liposome
ﬂoatation on a discontinuous sucrose gradient. Individual fractions
were analyzed by immunoblotting for Bcl-XL.
Found at doi:10.1371/journal.pbio.0060147.sg006 (569 KB TIF).
Text S1. Membrane-Bound Bcl-XL Can Exist in Both Functional and
Nonfunctional States
Found at doi:10.1371/journal.pbio.0060147.sd001 (36 KB DOC).
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